The research results of Sorafenib Injection presented by Koichi Pharmaceutical Company-B (02171) in "The Lancet" and the 2025 ASCO Annual Meeting.

Zhtng Cijng APP News, Kj Yoy - B (02171) released an announcement, announcing that the research results of the confirmatory Phase II clinical trial (CT041-ST-01, NCT04581473) of Shru J'o Lngsi Zhshy (product number: CT041, a CAR-T cell therapy candidate targeting Claudin18.2 protein) for patients with advanced gastric/esophageal-gastric junction adenocarcinoma who are Claudin18.2 positive and have failed at least second-line treatment in China have been fully published in "The Lancet" on May 31, 2025 (UK time), and were presented orally at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in a special session on gastrointestinal oncology on May 31, 2025 (Central Daylight Time).